SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Alivus Life Sciences Ltd

BSE: 543322 NSE: ALIVUS ISIN: INE03Q201024
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Alivus Life Sciences Ltd belong to?
Alivus Life Sciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Alivus Life Sciences Ltd a good quality company?
Alivus Life Sciences Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Alivus Life Sciences Ltd undervalued or overvalued?
Alivus Life Sciences Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Alivus Life Sciences Ltd a good buy now?
Alivus Life Sciences Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd revenue growth is 4.5% for FY-2025 , which is below its 5 year CAGR of 9.2% , indicating slower growth.
Q.2 Gross Profit margin of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 29.8% for FY-2025 , which is in line with its 5 year median of 29.8% , indicating stable margins.
Q.3 Operating Profit Margin of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 28.67% for FY-2025 , which is below its 5 year median of 29.59% indicating decreasing margins.
Q.4 Net Profit Margin of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Net Profit Margin is 20.35% for FY-2025 , is in line with with its 5 year median of 20.35%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 29.8 29.8
Operating Profit Margin 28.67 29.59
Net Profit Margin 20.35 20.35
Q.5 Return on Asset of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Return on Asset is 13.34%, which is below its 5 year historical median of 15.43%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Return on equity is 18.94% for FY-2025 , which is below its historical median of 22.33%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Return on capital employed is 25.5% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Cash conversion cycle is 151 days, above its historical median of 137 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.66 0.72
ROE 18.94 22.33
ROCE 25.5 30.01
Cash Conversion Cycle 151 days 137 days
Q.9 Debt to Equity ratio of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Alivus Life Sciences Ltd?
Promoters hold 74.87% of the Alivus Life Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Alivus Life Sciences Ltd vs industry peers?
Alivus Life Sciences Ltd revenue CAGR is 9.20% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 2,386.9 137.1
Gross Profit 711.3 15.1
Operating Profit 683 16
Net Profit 486 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.66 0.8
ROE 18.94 8.91
ROCE 25.5 11.59
Cash Conversion Cycle (days) 151.03 76

Valuation & price assessment

Q.1 Stock return of Alivus Life Sciences Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 36.42% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - 36.4% 8%
Q.3 Valuation ratios of Alivus Life Sciences Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 24.23 15.77 40.28
Price to Book 4.16 3.43 2.77
Price to Sales 5.24 3.46 2.65
EV to EBITDA 15.87 10.25 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×